Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

23.00USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$23.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
91,140
52-wk High
$35.52
52-wk Low
$20.66

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Announces U.S. FDA Approval Of Doptelet
Monday, 21 May 2018 12:43pm EDT 

May 21 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF DOPTELET® (AVATROMBOPAG).DOVA PHARMACEUTICALS INC - POSITIONED TO LAUNCH DOPTELET IN JUNE.  Full Article

FDA Approves Dova Pharma's New Drug For Patients With CLD Who Have Low Blood Platelets
Monday, 21 May 2018 11:55am EDT 

May 21 (Reuters) - U.S. FDA::FDA APPROVES NEW DRUG FOR PATIENTS WITH CHRONIC LIVER DISEASE WHO HAVE LOW BLOOD PLATELETS AND ARE UNDERGOING A MEDICAL PROCEDURE.FDA SAYS THE FDA GRANTED THE APPROVAL TO AKARX INC.  Full Article

Dova Pharmaceuticals Signs Distribution Agreement With Fosun Pharma For Mainland China And Hong Kong
Monday, 19 Mar 2018 08:00am EDT 

March 19 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH FOSUN PHARMA FOR MAINLAND CHINA AND HONG KONG.DOVA PHARMACEUTICALS - ‍DEAL THROUGH UNIT GRANTING FOSUN PHARMA EXCLUSIVE DEVELOPMENT,DISTRIBUTION RIGHTS OF AVATROMBOPAG IN MAINLAND CHINA, HONG KONG​.DOVA PHARMACEUTICALS INC - ‍TERMS OF TRANSACTION INCLUDE AN UPFRONT PAYMENT, MILESTONE PAYMENTS, AND A FIXED TRANSFER PRICE FOR PRODUCT SUPPLIED​.  Full Article

Dova Pharmaceuticals Says Public Offering Of 2.50 Mln Shares Priced At $32 per Share
Thursday, 22 Feb 2018 07:30pm EST 

Feb 22 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.50 MILLION COMMON SHARES PRICED AT $32.00 PER SHARE.  Full Article

Dova Pharma Files For Offering Of Up To 2.5 Mln Shares
Tuesday, 20 Feb 2018 04:27pm EST 

Feb 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Dova Pharmaceuticals Announces Proposed Offering Of Common Stock
Tuesday, 20 Feb 2018 04:05pm EST 

Feb 20 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 2.50 MILLION COMMON SHARES.  Full Article

Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​
Thursday, 15 Feb 2018 04:05pm EST 

Feb 15 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.DOVA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $‍0.36​.  Full Article

Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review
Monday, 27 Nov 2017 04:05pm EST 

Nov 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW.DOVA PHARMACEUTICALS INC - PDUFA GOAL DATE FOR AN FDA DECISION IS MAY 21, 2018 FOR NDA​.  Full Article

Dova Pharmaceuticals reports third quarter results
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals reports third quarter 2017 operating and financial results.Dova Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $0.38​.  Full Article

Dova Pharmaceuticals announces New Drug Application submission to FDA
Friday, 22 Sep 2017 07:00am EDT 

Sept 22 (Reuters) - Dova Pharmaceuticals Inc :Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist.Dova Pharmaceuticals Inc - ‍in both trials, avatrombopag met primary and secondary efficacy endpoints with high statistical significance​.Dova pharmaceuticals inc - ‍submission of a New Drug Application to U.S. Food and Drug Administration for avatrombopag​.  Full Article